Nasdaq
$8.55▲ 0.71%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $77.0MShares out 9.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 9.4After-hours26.09.05 07:204Ownership#●●●
Atara Biotherapeutics, Inc.
Brian Cherry, an insider at Atara Biotherapeutics, Inc., has filed a Power of Attorney to authorize designated representatives to complete and file necessary SEC reports, including Forms 3, 4, 5, and Form 144. This filing formalizes the delegation of authority for compliance with Section 16 of the Securities Exchange Act of 1934.…more
$8.55+0.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.26After-hours26.08.27 08:47144Ownership
Atara Biotherapeutics, Inc.
Atara Biotherapeutics insider Nguyen AnhCo filed an SEC Form 144 on August 26, 2026, to report a proposed sale of company securities. This filing formally discloses the insider's intent to sell shares, and investors should monitor this divestment activity.…more
$8.55+0.71%vs prev closeView filingShare - 8.26After-hours26.08.27 08:454Ownership
Atara Biotherapeutics, Inc.
Atara Biotherapeutics insider AnhCo Nguyen filed a Power of Attorney on August 26, 2026. This grants Kevin G. Sarney and Matthew A. Ebert the authority to act as attorneys-in-fact for filing SEC reports related to the insider's holdings and transactions.…more
$8.55+0.71%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:08#●●●#●●●
Atara Biotherapeutics Partner Receives FDA Acceptance for Tabelecleucel BLA Resubmission…more
Atara Biotherapeutics' partner, Pierre Fabre, has received FDA acceptance for the resubmission of the Biologics License Application for tabelecleucel to treat EBV+ PTLD. The FDA has set a PDUFA target action date of March 31, 2027, for the resubmission.…more
$8.55+0.71%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Pre-market26.09.30 21:09
●●●●●●●● ●●●●● ●●●●●●
Atara Biotherapeutics' partner, Pierre Fabre, has resubmitted the Biologics License Application for tabelecleucel to the FDA. This move marks a significant step in the regulatory process for the T-cell immunotherapy candidate.…more
$8.55+0.71%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report